Bosutinib (BOS) for previously treated patients with Philadelphia chromosome-positive (Ph plus ) leukemia: ≥8-year update of a phase 1/2 study

被引：0

作者：

Bruemmendorf, T. H. ^{[1
]}

Cortes, J. E. ^{[2
]}

Schafhausen, P. ^{[3
]}

Kindler, T. ^{[4
]}

Saussele, S. ^{[5
]}

Mueller, M. C. ^{[6
]}

Goh, Y. T. ^{[7
]}

Yilmaz, M. ^{[8
]}

Klisovic, R. B. ^{[9
]}

Purcell, S. ^{[10
]}

Viqueira, A. ^{[11
]}

Leip, E. ^{[12
]}

Gambacorti-Passerini, C. ^{[13
]}

机构：

[1] Univ Klinikum RWTH Aachen, Aachen, Germany

[2] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[3] Univ Canc Ctr Hamburg, Dept Internal Med 2, Hubertus Wald Tumor Ctr, Hamburg, Germany

[4] Univ Med Mainz, Med Klin & Poliklin 3, Mainz, Germany

[5] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany

[6] Inst Hematol & Oncol IHO GmbH, Mannheim, Germany

[7] Singapore Gen Hosp, Bukit Merah, Singapore, Singapore

[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX 77030 USA

[9] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[10] Pfizer Ltd, Walton Oaks, England

[11] Pfizer SLU, Madrid, Spain

[12] Pfizer Inc, Cambridge, MA USA

[13] Univ Milano Bicocca, Monza, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：74 / 74

页数：1